arrow
S

Spyridon Gennatas

guy's and st. thomas' nhs foundation trust
H指数:18
被引数:2,939

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Predictors and Outcomes of Non-Small Cell Lung Carcinoma Patients Following Severe Immune Checkpoint Inhibitor Toxicity: A Real-World UK Multi-Centre Study

非小细胞肺癌患者发生严重免疫检查点抑制剂毒性的预测因素与结局:一项英国多中心真实世界研究

Cancers
IF4.4
2026-03-030
OAAI
COVID-19 in cancer patients: update from the joint analysis of the ESMO-CoCARE, BSMO, and PSMO international databases

癌症患者的新型冠状病毒肺炎: 来自esmo-cocare,BSMO和PSMO国际数据库联合分析的更新

2023-06-012
OAAI
Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries

免疫检查点抑制剂治疗和癌症患者SARS-CoV-2感染的结果: OnCovid和esmo-cocare注册中心的联合分析

2022-11-305
OAAI
COVID-19 in patients with cancer: first report of the ESMO international registry-based, cohort study (ESMO-CoCARE)

癌症患者的新型冠状病毒肺炎: 基于ESMO国际注册的队列研究 (esmo-cocare) 的第一份报告

2022-06-0120
OAAI
Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital
2022-05-014
OAAI
Integrated genomics point to immune vulnerabilities in pleural mesothelioma (vol 11, 19138, 2021)

综合基因组学指出胸膜间皮瘤的免疫脆弱性 (第11卷,19138,2021)

2022-03-210
OAAI
Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study
2021-10-2744
OA
Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study
2021-10-0522
OAAI
Integrated genomics point to immune vulnerabilities in pleural mesothelioma

整合基因组学指向胸膜间皮瘤的免疫脆弱性

2021-09-2717
OAAI